

https://dspace.org/

Factors impacting on left ventricular hypertrophy in haemodialysis patients

Chabu, James

2008-10-23T08:35:25Z
http://hdl.handle.net/10539/5802

Downloaded from a DSpace repository. https://dspace.org/

REFERENCES

ABERGEL E, TASE M, BOHLENDER J, MENARD J & CHATELLIER G (1995) Which Definition for Echocardiographic Left Ventricular Hypertrophy? *Am J Cardiol,* 75**,** 498-502.

ACHINGER SG & AYUS JC (2005) The role of vitamin D in left ventricular hypertrophy and cardiac function. *Kidney Int,* 67**,** s37-s42.

AGABA E I, ADENIYI O, SERVILLA KS, VANDERJAGT DJ, GLEW RH & TZAMALOUKAS AH (2004) characteristics of end stage renal disease diabetic patients in two countries with different socioeconomic conditions. *International Urology and Nephrology,* 36**,** 611-616.

AGARWAL R & LEWIS RR (2001) Prediction of hypertension in chronic hemodialysis patients. *Kidney International,* 60**,** 1982-1989.

AGARWAL R, NISSENSON AR, BATLLE D, COYNE DW, TROUT JR & WARNOCK DG (2003) Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. *Am J Med,* 115**,** 291-297.

AGARWAL R, PEIXOTO AJ, SANTOS SFF & ZOCCALI C (2006) Pre- and Postdialysis Blood Pressures Are Imprecise Estimates of Interdialytic Ambulatory Blood Pressure. *Clinical Journal of the American Society of Nephrology.*

AGODOA LY & EGGERS PW (1995) Renal replacement therapy in the United States: Data from the United States Renal Data System. *Am J Kidney Dis,* 25**,** 119-133.

AHMED SH, CLARK LL, PENNINGTON WR, WEBB CS, BONNEMA DD, LEONARDI AH, MCCLURE CD, SPINALE FG & ZILE MR (2006) Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases.Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease. *Circulation,* 113**,** 2089-2096.

AIMES RT & QUIGLEY JP (1995) Matrix metalloproteinase-2 is an interstitial collagenase: inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific - and -length fragments. *J Biol Chem,* 270**,** 5872-5876.

AMANN K, GASSMANN P, BUZELLO M, ORTH SR, TORNIG J, GROSS ML, MAGENER A, MALL G & RITZ E (2000) Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats. *Kidney Int,* 58**,** 153-161.

AMANN K, RITZ E, WIEST G, KLAUS G & MALL G (1994) A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. *J Am Soc Nephrol,* 4**,** 1814-1819.

ANDERSEN MJ, KHAWANDI W & AGARWAL R (2005) Home blood pressure monitoring in CKD. *Am J Kidney Dis,* 45**,** 994.

ANDERSON JV, RAINE AE, PROUDLER A & BLOOM SR (1986) Effect of haemodialysis on plasma concentrations of atrial natriuretic peptide in adult patients with chronic renal failure. *J Endcrinol,* 110**,** 193-196.

ANDO Y, TABEI K, SHIINA A, ASANO Y & HOSODA S (1985) Ultrasonographic evaluation of changes in the inferior vena caval configuration during hemodialysis:

Relationship between the amount of water removed and the diameter of the inferior vena cava. *Jap J Soc Dial Ther,* 18**,** 173-179.

ANDREW P (2003) Diastolic heart failure demystified. *chest,* 124**,** 744-753.

ANTMAN EM, ANBE DT, ARMSTRONG PW, BATES ER, GREEN LA, HAND M, HOCHMAN JS, KRUMHOLZ HM, KUSHNER FG, LAMAS GA, MULLANY CJ, ORNATO JP, SLOAN MA, SMITH SC JR, ALPERT JS, ANDERSON JL, F. D., FUSTER V, GIBBONS RJ, GREGORATOS G, HALPERIN JL, HIRATZKA LF, HUNT SA, JACOBS AK & ORNATO JP (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. *J Am Coll Cardiol.,* 44**,** E1-E211.

ASMAR RG, PANNIER B, SANTONI JP, LAURENT S, LONDON GM, LEVY BI & SAFAR ME (1988) Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. *Circulation,* 78**,** 941-950.

BAGUET JP, MOREAU -GAUDRY A, SICHE JP, DOUCHIN SS, TREMEL F & MALLION JM (2000) Carotid remodeling in essential hypertension:role of blood pressure,indexed parameters,and association with cardiac mass and aortic stiffness. *Clin and exper hypertension,* 22**,** 717-729.

BAKER A H, EDWARDS D R & MURPHY G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. *Journal of Cell Science,* 115**,** 3719-3727.

BARNES MJ & FARNDALE RW (1999) Collagens and atherosclerosis. *Exp Gerontol,* 34**,** 513-525.

BENETOS A, ADAMOPOULOS C, BUREAU J-M, TEMMAR M, LABAT C, BEAN K, THOMAS F, PANNIER B, ASMAR R, ZUREIK M, SAFAR M & GUIZE L (2002)

Determinants of accelerated progression of arterial stiffness in normotensive and treated hypertensive subjects over a 6-year period. *Circulation,* 105**,** 1202-1207.

BLACHER J, GUERIN AP, PANNIER B, MARCHAIS SJ, SAFAR ME & LONDON GM (1999) Impact of aortic stiffness on survival in end-stage renal disease. *Circulation,* 99**,** 2434-2439.

BLACHER J, LONDON GM, SAFAR ME & MOURAD JJ (1999) Influence of age and end-stage renal disease on the stiffness of carotid wall material in hypertension. *J Hypertens.,* 17**,** 237-244.

BLACHER J, SAFAR ME, GUERIN AP, PANNIER B, MARCHAIS SJ & LONDON GM (2003) Aortic pulse wave velocity index and mortality in end-stage renal disease. *Kidney Int.,* 63**,** 1852-1860.

BOUTHIER JD, DE LUCA N, SAFAR ME & SIMON AC (1985) Cardiac and arterial distensibility in essential hypertension. *Am Heart J,* 109**,** 1345-1352.

BOUTOUYRIE P, LAURENT S, GIRERD X & ET AL (1995) Common carotid artery stiffness and patterns of left ventricular hypertrophy in hypertensive patients. *Hypertension,* 25**,** 651-659.

BRENNAN JM, RONAN A, GOONEWARDENA S, BLAIR JEA, HAMMES M, SHAH D, VASAIWALA S, KIRKPATRICK JN & SPENCER KT (2006) Handcarried Ultrasound Measurement of the Inferior Vena Cava for Assessment of Intravascular Volume Status in the Outpatient Hemodialysis Clinic. *Clin J Am Soc Nephrol,* 1**,** 749-753.

BRIGHT R (1836) Cases and observations, illustrative of renal disease accompanied with the secretion of albuminous urine. *Guys Hosp Rep,* 1**,** 338.

CHAIGNON M, CHEN WT, TARAZI RC, BRAVO EL & NAKAMOTO S (1981) Effect of hemodialysis on blood volume distribution and cardiac output. *Hypertension,* 3**,** 327-332.

CHAMIOT CLERC P, RENAUD JF, BLACHER J, LEGRAND M, SAMUEL JL, LEVY BI, SASSARD J & SAFAR ME (1999) Collagen I and III and mechanical properties of conduit arteries in rats with genetic hypertension. *J Vasc Res,* 36**,** 139-146.

CHANG H-R, S-F', Y., LI M-LB, LIN C-C, HSIEH Y-SC & LIAN J-D (2006) Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. *Clinica Chimica Acta,* 366**,** 243 - 248.

CHARRA B, CALEMARD E, CUCHE M & LAURENT G (1983) Control of hypertension and prolonged survival on maintenance hemodialysis. *Nephron,* 33**,** 96-99.

CHEN CH, TING CT, LIN SJ, HSU T L, HO **S J**, CHOU P, CHANG M.S, O. C. F., SPURGEON H., LAKATTA E. & YIN F C (1998) Which arterial and cardiovascular parameters best predict left ventricular mass? *Circulation,* 98**,** 422-428.

CHERIEX EC, LEUNISSEN KML, JANSSEN JHA, MOOY JMV & VAN HOOFF JP (1989) Echography of the inferior vena cava is a simple and reliable tool for estimation of ‘dry weight’ in haemodialysis patients. *Nephrol Dial Transplant,* 4**,** 563-568.

CHEUNG AK, SARNAK MJ, YAN G, DWYER JT, HEYKA RJ, ROCCO MV & AND THE HAEMODIALYSIS (HEMO) STUDY (2000) Atherosclerotic cardiovascular disease risks in chronic haemodialysis patients. *Kidney Int,* 58**,** 353-362.

CHOBANIAN AV, BAKRIS GL, BLACK HR, CUSHMAN WC, GREEN LA, IZZO JL JR, JONES DW, MATERSON BJ, OPARIL S, WRIGHT JT JR, ROCCELLA EJ & NATIONAL HEART, L., AND BLOOD INSTITUTE JOINT NATIONAL

COMMITTEE ON PREVENTION, DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE,NATIONAL HIGH BLOOD PRESSURE EDUCATION PROGRAM COORDINATING COMMITTEE, (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *Hypertension,* 42**,** 1206-52.

CHOU F-P, CHUB S-C, CHENG M-C, YANGA S-F, CHEUNG W-N, CHIOUD H-L & HSIEH Y-S (2002) Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. *Clinical Biochemistry,* 35**,** 383-388.

CLYNE N, LINS LE & PEHRSSON SK (1986) Occurrence and significance of heart disease in uraemia.An autopsy study. *Scand J Urol Nephrol,* 20**,** 307-311.

CONLON PJ, WALSHE JJ, HEINLE SK, MINDA S, KRUCOFF M & SCHWAB SJ (1996) predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable haemodialysis patients. *J Am Soc Nephrol,* 7**,** 2658-2663.

COOMER RW, SCHULMAN G, BREYER JA & SHYR Y (1997) Ambulatory blood pressure monitoring in dialysis patients and estimation of mean interdialytic blood pressure. *Am J Kidney Dis,* 5**,** 678-84.

COVIC A, GOLDSMITH DJ & COVIC M (2000) Reduced blood pressure diurnal variability as a risk factor for progressive left ventricular dilatation in hemodialysis patients. *Am J Kidney Dis,* 35**,** 617-23.

COVIC A, GOLDSMITH DJ, PANAGHIU L, COVIC M & SEDOR J (2000) Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms. *Kidney Int,* 57**,** 2634-2643.

COWIE MR, STRUTHERS AD, WOOD DA, COATS AJ, THOMPSON SG, POOLE-WILSON PA & SUTTON GC (1997) Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. *The Lancet,* 350**,** 1349-1353.

DAHAN M, SIOHAN P, VIRON B, MICHEL C, PAILLOLE C, R, G. & MIGNON F (1997) Relationship between left ventricular hypertrophy, myocardial contractility, and load conditions in hemodialysis patients: an echocardiographic study. *Am J Kidney Dis,* 30**,** 780-785.

DE BOLD AJ, MA KK, ZHANG Y, DE BOLD MLK, BENSIMON M & KHOSHBATEN A (2001) The physiological and pathophysiological modulation of the endocrine function of the heart. *Can J Physiol Pharmacol,* 79**,** 705-714.

DE PALO EF, WOLOSZCZUK W, MENEGHETTI M, DEPALO CB, NIELSEN HB & SECHER NH (2000) Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. *Clin Chem,* 46**,** 843-847.

DEAGUE JA, WILSON CM, GRIGG LE & HARRAP SB (2001) Physiological relationships between central vascular haemodynamics and left ventricular structure. *Clin Sci,* 101**,** 79-85.

DEVEREAUX RB, LUTAS EM, CASALE RN, KLIGFIELD P, EISENBERG RR, HAMMOND IW, MILLER DH, REIS G, ALDERMAN MH & LARAGH JH (1984) Standardization of M-mode echocardiographic left ventricular anatomic measurements. *J Am Coll Cardiol,* 4**,** 1222-1230.

DEVEREUX RB, ALONSO DR, LUTAS EM, GOTTLIEB GJ, CAMPO E, SACHS I & REICHEK N (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol,* 57**,** 450-458.

DEVEREUX RB, ROMAN MJ, PALMIERI V, OKIN PM, BOMAN K, GERDT E, NIEMINEN MS, V, P., WACHTELL K & DAHLOF B (2000) Left ventricular wall

stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. *Journal of Hypertension,* 18**,** 1129-1138.

EGHBALI M, TOMEK R, SUKHATME VP, WOODS C & BHAMBI B (1991) Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. *Circ Res,* 69**,** 483-90.

ERTUK S, ERTUG A, ATES K, DUMAN N, ASLAN SM, NERGISOGLU G, DIKER E, EROL C, KARATAN O & ERBAY B (1996) Relationship of ambulatory blood pressure monitoring data to echocardiographic findings in haemodialysis patients. *Nephrol Dial Transplant,* 11**,** 2050-4.

ERTURK, ERTUG AE, ATES K, DUMAN N, ASLAN SM, NERGISOGLU G, DIKER E, EROL C, KARATAN O & ERBAY B (1996) Relationship of ambulatory blood pressure monitoring data to echocardiographic findings in haemodialysis patients. *Nephrol Dial Transpl,* 11**,** 2050-2054.

ESCHBACH JW (1989) The anemia of chronic renal failure. *Kidney Int,* 35**,** 134-148.

ESCHBACH JW, AQUILING T, HALEY NR, FAN MH & BLAGG CR (1992) The long-term effects of recombinant human erythropoietin on the cardiovascular system. *Clin Nephrol.,* 38**,** S98-103.

FAGARD R, STAESSEN J, THIJS L & AMERY A (1995) Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoring. A meta-analysis of comparative studies. *Am J Hypertens,* 8**,** 533-540.

FAGARD RH, STAESSEN JA & THIJS L (1997) Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. *Hypertension,* 29**,** 22-29.

FAGUGLI RM, PALUMBO B, RICCIARDI D, PASINI P, SANTIROSI P, VECCHI L, PASTICCI F & PALUMBO R (2003) Association between brain natriuretic peptide and extracellular water in hemodialysis patients. *Nephron Clin Pract.,* 95**,** c60-6.

FOLEY RN, MURRAY AM, LI S, HERZOG CA, MCBEAN AM, EGGERS PW & COLLINS AJ (2005) Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. *J Am Soc Nephrol,* 16**,** 489-95.

FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MARTIN CJ, MURRAY DC & BARRE PE (1995) Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. *Kidney Int,* 47**,** 186-192.

FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MURRAY DC & BARRE PE (1996) Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. *Kidney Int,* 49**,** 1379-85.

FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MURRAY DC & BARRE PE (1996) The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. *Am J Kidney Dis,* 28**,** 53-61.

FOLEY RN, PARFREY PS, MORGAN J, BARRE PE, CAMPBELL P, CARTIER P, COYLE D, FINE A, HANDA P, KINGMA I, LAU CY, LEVIN A, MENDELSSOHN D, MUIRHEAD N, MURPHY B, PLANTE RK, POSEN G & WELLS GA (2000) Effect of haemoglobin levels in haemodialysis patients with asymptomatic cardiomyopathy. *Kidney Int.,* 58**,** 1325-1335.

FOLEY RN, PARFREY PS & SARNAK MJ (1998) Cardiovascular disease in chronic renal disease: Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis,* 32**,** 112-119.

FRANZ M, WOLOSZCZUK W & HORL WH (2000) N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. *Kidney Int,* 58**,** 374-383.

FUJII H, KIM J I, ABE T, UMEZU M & FUKAGAWA (2007) Relationship between Parathyroid hormone and Cardiac Abnormalities in chronic Dialysis Patients. *Internal Medicine***,** 1507-1512.

GARDNER DG, WIRTZ H & DOBBS LG (1992) Stretch-dependent regulation of atrial peptide synthesis and secretion in cultures atrial cardiocytes. *Am J Physiol,* 263**,** E239-E244.

GATES PE, TANAKA H, GRAVES J & SEALS DR (2003) Left ventricular structure and diastolic function with human ageing. Relation to habitual exercise and arterial stiffness. *Eur Heart J,* 24**,** 2213-2220.

GILL GV & OUWERKERK J (1995) Changing patterns of medical diease in Soweto, South Africa 1981-1990. *Tropical Doctor,* 25**,** 171-172.

GOODMAN WG & DANOVITCH GM (2004) *Options for Patients with Kidney Failure,* Philadelphia, Lippincott Williams & Wilkins.

GUEDERS M M, FOIDART JM, NOEL A & CATALDO D D (2006) Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: Potential implications in asthma and other lung diseases [review]. *European Journal of Pharmacology,* 533**,** 133-144.

GUERIN AP, LONDON GM, MARCHAIS SJ & METIVIER F (2000) Arterial stiffening and vascular calcifications in end-stage renal disease. *Nephrol Dial Transplant,* 15**,** 1014-1021.

HAKIM JG, GEORGE A & SIZIYA S (1996) Echocardiographic assessment of left ventricular hypertrophy diastolic dysfunction and pericardial disease in patients on maintenance haemodialysis. *East Afr Med J,* 73**,** 505-8.

HARNETT JD, KENT GM, BARRE PE, TAYLOR R & PARFREY PS (1994) Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. *J Am Soc Nephrol,* 4**,** 1486.

HARNETT JD, MURPHY B, COLLINGWOOD P, PURCHASE L, KENT G & PARFREY PS (1993) The reliability and validity of echocardiographic assessment of left ventricular mass index in hemodialysis patients. *Nephron,* 65**,** 212-214.

HASEGAWA K, MATSUSHITA Y, INOUC T, MORII H, ISHIBASHI M & YAMAJI T (1986) Plasma levels of atrial natriuretic peptide in patients with chronic renal failure. *J Clin Endocrinol Metab,* 63**,** 819-822.

HASHIMOTO J, IMAI Y & O'ROURKE M F (2007) Monitoring of Antihypertensive Therapy for Reduction in Left ventricular Mass. *AJH,* 20**,** 1229-1233.

HAYDAR AA, COVIC A, COLHOUN H, RUBENS M & GOLDSMITH DJA (2004) Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. *Kidney Int.,* 65**,** 1790-1794.

HUMPHREYS MH & VALENTIN J-P (2000) *Natriuretic humoral agents,* Philadelphia, Lippincott Williams & Wilkins.

ICHIHARA A, H. M., RYUZAKI M, HANDA M, FURUKAWA T, SARUTA T. (2002) Fluvastatin prevents development of arterial stiffness in hemodialysis patients with type 2 diabetes mellitus. *Nephrol Dial Transplant,* 17**,** 1513-1517.

IKETANI T, IKETANI Y, TAKAZAWA K & YAMASHINA A (2000) The influence of the peripheral reflection wave on left ventricular hypertrophy in patients with essential hypertension. *Hypertens Res,* 23**,** 451-458.

ISHIKURA F, ANDO Y, PARK YD, TANI A, SHIRAI D, MATSUOKA H & MIYATAKE K (1996) Changes of plasma atrial and brain natriuretic peptide levels during hemodialysis. *Ren Fail.,* 18**,** 261-270.

JAEGER JQ & MEHTA RL (1999) Assessment of Dry Weight in Hemodialysis:An Overview. *J Am Soc Nephrol,* 10**,** 392-403.

JOFFY S & ROSNER M H (2005) Natriuretic Peptides in ESRD. *Am J Kidney Dis,* 46**,** 1-10.

JOHNSTONE LM, JONES CL, GRIGG LE, WILKINSON JL, WALKER RG & POWELL H (1996) Left ventricular abnormalities in children, adolescents and young adults with renal disease. *Kidney Int.,* 50**,** 998-1006.

KADDOURA S (2002) *Echo made easy,* London, Churchill Livingstone.

KEITH DS, NICHOLS GA, GULLION CM, BROWN JB & SMITH DH (2004) Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. *Arch Intern Med.,* 164**,** 659-63.

KIM HW, PARK CW, SHIN YS, KIM YS, SHIN SJ, KIM Y, CHOI EJ, CHANG YS & BANG BK (2006) Calcitriol Regresses Cardiac Hypertrophy and QT Dispersion in Secondary Hyperparathyroidism on Hemodialysis. *Nephron Clin Practice.,* 102**,** c21-c29.

KING GL & WAKASAKI H (1999) Theoretical mechanisms by which hyperglycaemia and insulin resistance could cause cardiovascular diseases in diabetes. *Diabetes Care,* 22**,** C25-C30.

KINGWELL AB & CAMERON JD (2006) *Non pharmacological treatment for increased arterial stiffness and altered wave reflections.,* Amsterdam, Elsevier.

KOHSE K, FEIFEL K & MAYER-WEHRSTEIN R (1993) Differential regulation of brain and atrial natriuretic peptides in hemodialysis patients. *Clin Nephrol.,* 40**,** 83-90.

KONE BC (2001) Molecular biology of natriuretic peptides and nitric oxide synthases. *Cardiovasc Res,*51**,** 429-441.

KOREN MJ, DEVEREUX RB, CASALE PN, SAVAGE DD & LARAGH JH (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. *Ann Intern Med,* 114**,** 345-352.

KORZETS Z, ERDBERG A, GOLAN E & BERNHEIM J (1994) Does diurnal variation in blood pressure exist in CAPD patients? *Nephrol Dial Transplant,* 9**,** 274-276.

KOUW PM, KOOMAN JP, CHERIEX EC, OLTHOF CG, DEVRIES PM & LEUNISSEN KM (1993) Assessment of post dialysis dry weight: A comparison of techniques. *J Am Soc Nephrol,* 4**,** 98-104.

KRAEMER M, RODE C & WISEMAN V (2006) Detection limit of methods to assess fluid status changes in dialysis patients. *Kidney Int,* 69**,** 1609-1620.

LANG R M, BIERIG M, DEVEREUX R B, FLACHSKAMPF FA, FOSTER E, PELLIKKA PA, PICARD MH, ROMAN MJ, SEWARD J, SHANEWISE JS, SOLOMON SD, SPENCER KT, SUTTON MS & STEWART WJ (2005) Recommendations for chamber Quantification:A Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. *J Am Soc Echocardiogr,* 18**,** 1440-1463.

LANTELME P, MESTRE C, LIEVRE M, GRESSARD A & MILON H (2002) Heart rate an important confounder of pulsewarve velocity assessment. *Hypertention,* 39**,** 1083-1087.

LAURENT S, BOUTOUYRIE P, ASMAR R, GAUTIER I, LALOUX B, GUIZE L, DUCIMETIERE P & BENETOS A (2001) Aortic stiffness is an independent predictor of all-cause cardiovascular mortality in hypertensive patients. *Hypertension,* 37**,** 1236-1241.

LAUSTER F, FULLE HJ, GERZER R & SCHIFFL H (1992) The postdialytic plasma cyclic guanosine 3959-monophosphate level as a measure of fluid overload in chronic haemodialysis. *J Am Soc Nephrol,* 2**,** 1451-1454.

LAUSTER F, GERZER R, WEIL J, FULLE HJ & SCHIFF H (1990) Assessment of dry body weight in hemodialysis patients by the biochemical marker cGMP. *Nephrol Dial Transplant,* 5**,** 356-361.

LAUSTER F, HEIM JM, DRUMMER C, FULLE HJ, GERZER R & SCHIFFL H (1993) Plasma cGMP level as a marker of the hydration state in renal replacement therapy. *Kidney Int,* 41**,** 57-59.

LAVIADES C, VARO N, FERNANDEZ J, MAYOR G, GIL MJ, MONREAL I & DIEZ J (1998) Abnormalities of the extracellular degradation of collagen type I in essential hypertension. *Circulation,* 98**,** 535-540.

LEE AA, DELHAAS T, MCCULLOCH AD & VILLARREAL FJ (1999) Differential responses of adult cardiac fibroblasts to in vitro biaxial strain patterns. *J Mol Cell Cardiol,* 31**,** 1833-43.

LEE SW, SONG JH, KIM GA, LIM HJ & KIM MJ (2003) Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. *Am J Kidney Dis,* 41**,** 1257-1266.

LEKAKIS JP, ZAKAPOULOS NA, PROTOGEROU AD, KOTSIS VT, PAPAIOANNOU TG, STAMATELOPOULOS KS, TSITSRICOS MD, PITIRIGA VC, PAPAMICHAEL CM, TOUMANIDES ST & MAVRIKAKIS ME (2004) Cardiac hypertrophy in hypertension: relation to 24-hour blood pressure profile and arterial stiffness. Int J Cardiol, 97, 29-33.

LEONCINI G, RATTO E, VIAZZI F, VACCARO V, PARODI A, FALQUI V, CONTI N, TOMOLILLO C, DEFERRARI G & PONTREMOLI R (2006) Ambulatory arterial stiffness index is associated with target organ damage in primary hypertension. Hypertension, 48, 397-403.

LEUNISSEN KM, KOUW P, KOOMAN JP, CHERIEX EC, DEVRIES PM, DONKER AJ & VAN HOOFF JP (1993) New techniques to determine fluid status in hemodialyzed patients. *Kidney Int,* 43**,** 50-56.

LEUNISSEN KM, MENHEERE PP, CHERIEX EC, VAN DEN BERG BW, NOORDZIJ TC & VAN HOOFF JP (1989) Plasma alpha-human atrial natriuretic peptide and volume status in chronic hemodialysis patients. *Nephrol Dial Transplant,* 4**,** 382-386.

LEVIN A, SINGER J, THOMPSON CR, ROSS H & LEWIS M (1996) Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. *Am J Kidney Dis,* 3**,** 347-54.

LEVIN A, SINGER J, THOMPSON CR, ROSS H & LEWIS M (1996) Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. *Am J Kidney Dis,* 27**,** 347-354.

LEVIN A, THOMPSON CR, ETHIER J, CARLISLE EJF, TOBE S, MENDELSSOHN D, BURGESS E, JINDAL K, BARRETT B, SINGER J & DJURDJEV O (1999) Left ventricular mass index in early renal disease. Impact of a decline in hemoglobin. *Am J Kidney Dis,* 34**,** 125 -134.

LEVY D, GARRISON RJ, SAVAGE DD, KANNEL WB & CASTELLI WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med.,* 322**,** 1561-1566.

LIJNEN PJ, PETROV VV & FAGARD RH (2001) Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. *J Renin Angiotensin Aldosterone Syst,* 2**,** 117-22.

LIMAS C, WESTRUM B, LIMAS CJ & COHN JN (1980) Effect of salt on the vascular lesions of spontaneously hypertensive rats. *Hypertension,* 2**,** 477-489.

LIN YP, CHEN CH, YU WC, HSU TL, DING PY & YANG WC (2002) Left ventricular mass and haemodynamic overload in normotensive haemodialysis patients. *Kidney Int,* 62**,** 1828-1838.

LIN YP, Y. W., HSU TL, DING PY,YANG WC, CHEN CH (2003) The extracellular fluid-to-intracellular fluid volume ratio is associated with large-artery structure and function in hemodialysis patients. *Am J Kidney Dis,* 42**,** 990-9.

LINS RL, ELSEVIERS M, ROGIERS P, VAN HOEYWEGEN RJ, DE RAEDT H, ZACHEE P & DAELEMANS RA (1997) Importance of volume factors in dialysis-related hypertension. *Clin Nephrol,* 48**,** 29-33.

LONDON GM, BLACHER J, PANNIER B, GUERIN A, MARCHAIS S & SAFAR M (2001) Arterial wave reflections and survival in end-stage Renal Failure. *Hypertension,* 38**,** 434-38.

LONDON GM & FABIANI F (1992) *Left ventricular dysfunction in end-stage renal disease: Echocardiographic insights.*, Basel, Kluwer Academic Publishers.

LONDON GM, FABIANI F, MARCHAIS SJ, DE VERNEJOUL MC, GUERIN AP, SAFAR ME, METIVIER F & LLACH F (1987) Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. *Kidney Int,* 31**,** 973-980.

LONDON GM, GUERIN AP & MARCHAIS SJ (1999) Pressure overload cardiomyopathy in end stage renal disease. *Curr Opin Nephrol hypertens,* 8**,** 179-186.

LONDON GM, GUERIN AP, MARCHAIS SJ, PANNIER B, SAFAR ME, DAY M & METIVIER F (1996) Cardiac and arterial interactions in end-stage renal disease. *Kidney Int,* 50**,** 600-608.

LONDON GM, MARCHAIS SJ, GUERIN AP, METIVIER F & ADDA H (2002) Arterial structure and function in end-stage renal disease. *Nephrol Dial Transplant,* 17**,** 1713-1724.

LONDON GM, MARCHAIS SJ, GUERIN AP, METIVIER F, ADDA H & PANNIER B (2003) Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. *Kidney Int,* S84**,** 88-93.

LONDON GM, MARCHAIS SJ, SAFAR ME, GENEST AF, GUERIN AP, METIVIER F, CHEDID K & LONDON AM (1990) Aortic and large artery compliance in end stage renal disease. *Kidney Int,* 37**,** 137-142.

LONDON GM & PARFREY PS (1997) Cardiac disease in chronic uremia: pathogenesis. *Adv Ren Replace Ther,* 4**,** 194-211.

LONGENECKER JC, CORESH J, POWE NR, LEVEY AS, FINK NE, MARTIN A & KLAG MJ (2002) Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. *J Am Soc Nephrol,* 13**,** 1918-1927.

LONGO GM, XIONG W, GREINER TC, ZHAO Y, FIOTTI N & BAXTER BT (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. *J Clin Invest,* 110**,** 625-632.

MACKENNA D, SUMMEROUR SR & VILLARREAL FJ (2000) Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. *Cardiovasc Res,* 46**,** 257-263.

MALVINDER S PARMAR (2002) Chronic renal disease. *BMJ,* 325**,** 85-90.

MANCIA G, DE BACKER G, DOMINICZAK A & ET AL (2007) Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens,* 25**,** 1105.

MANCIA G & PARATI G (2000) Ambulatory blood pressure monitoring and organ damage. *Hypertension,* 36**,** 894-900.

MANN JF, GERSTEIN HC, POGUE J, BOSCH J & YUSUF S (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of Ramipril: the HOPE randomized trial. *Ann Intern Med,* 134**,** 629-636.

MASSRY SG & SMOGORZWESKI M (1994) Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. *Semin Nephrol,* 14**,** 219 -231.

MATSUMOTO Y, HAMADA M & HIWADA K (2000) Aortic distensibility is closely related to the progression of left ventricular hypertrophy in patients receiving hemodialysis. *Angiology,* 51**,** 933-941.

MCDONAGH TA, ROBB SD, MURDOCH DR, MORTON JJ, FORD I, MORRISON CE, TUNSTALL-PEDOE H, MCMURRAY JJ & DARGIE HJ (1998) Biochemical detection of left-ventricular systolic dysfunction. *Lancet,* 351**,** 9-13.

MCGREGOR E, JARDINE AG, MURRAY LS, DARGIE HJ, RODGER RS, JUNOR BJ, MCMILLAN MA & BRIGGS JD (1998) Pre-operative echocardiographic abnormalities and adverse outcome following renal transplantation. *Nephrol Dial Transpl,* 13**,** 1499-1505.

MCNULTY M, MAHMUD A, SPIERS P & FEELY J (2006) Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. *Journal of Human Hypertension,* 20**,** 867-873.

METRY G, HALL C, WIKSTROM B, KALLSKOG V, HANSELL P & DANIELSON B (2001) Fluid balance in patients with chronic renal failure assessed with N-terminal proatrial natriuretic peptide, atrial natriuretic peptide and ultrasonography. *Acta Physiol Scand,* 171**,** 117-122.

MIDDLETON RJ, PARFREY PS & FOLEY RN (2001) Left Ventricular Hypertrophy in the Renal Patient. *J Am Soc Nephrol,* 12**,** 1079-1084.

MIDDLETON RJ, PARFREY PS, FOLEY RN & (2001) Left Ventricular Hypertrophy in the Renal Patient. *J Am Soc Nephrol,* 12**,** 1079-1084.

MITSNEFES MM, DANIELS SR, SCHWARTZ SM, MEYER RA, KHOURY P & STRIFE CF (2000) Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. *Pediatr Nephrol,* 14**,** 898-902.

MORSE SA, DANG A, THAKUR V, ZHANG R & REISIN E (2003) Hypertension in chronic dialysis patients: pathophysiology, monitoring and treatment. *Am J Med Sci,* 325**,** 194-201.

MOSTELLER RD (1987) Simplified calculation of body surface area. *N Engl J Med,* 317**,** 1098.

NABOKOV AV, AMANN K, WESSELS S, MUNTER K, WAGNER J & RITZ E (1999) Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. *Kidney Int,* 55**,** 512-519.

NAGANUMA T, SUGIMURA K, WADA S, YASUMOTO R, SUGIMURA T, MASUDA C, UCHIDA J & NAKATANI T (2002) The prognostic role of brain natriuretic peptides in hemodialysis patients. *Am J Nephrol,* 22**,** 437-444.

NAGASE H & WOESSNER JF JR (1999) Matrix metalloproteinases. *J Biol Chem,* 274**,** 21491-21494.

NAKAO K, OGAWA Y, SUGA S & IMURA H (1992) Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. *J Hypertens,* 10**,** 1111-1114.

NASRI H, BARADARAN A & NADERI AS (2004) Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. *Acta Med Austriaca,* 31**,** 67-72.

NATIONAL KIDNEY FOUNDATION (2005) K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. *Am J Kidney Dis,* 45**,** 16-153.

NEUMANN S, HUSE K, SEMRAU R, DIEGELER A, GEBHARDT R, BUNIATIAN GH & SCHOLZ GH (2002) Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. *Hypertension,* 39**,** 756-60.

NICHOLS WW & O'ROURKE MF (1998) *McDonald's Blood Flow in Arteries,* London, Arnold.

NITTA K, AKIBA T, UCHIDA K, OTSUBO S, OTSUBO Y, TAKEI T, OGAWA T, YUMURA W, KABAYA T & NIHEI H (2004) Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. *Hypertens Res,* 27**,** 47-52.

NKF (2002) K/DOQI clinical practice guidelines for Chronic Kidney Disease: evaluation, classification and stratification. *Am J Kidney Dis,* 39.

NORTON, G. R., WOODIWISS, A. J., GAASCH, W. H., MELA, T., CHUNG, E. S., AURIGEMMA, G. P. & MEYER, T. E. (2002) Heart failure in pressure overload hypertrophy: The relative roles of ventricular remodeling and myocardial dysfunction. *J Am Coll Cardiol,* 39**,** 664-671.

ORI Y, KORZETS A, KATZ M, ERMAN A, WEINSTEIN T, MALACHI T & GAFTER U (2002) The contribution of an arteriovenous access for hemodialysis to left ventricular hypertrophy. *Am J Kidney Dis,* 40**,** 745-52.

ÖZHAHYA M, OK E, CIRIT M, AYDIN S, AKCICEK F, BASCIA A & MEES E. J. D (1998) Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. *Nephrol Dial Transplant,* 13**,** 1489-1493.

PANTEGHINI M & CLERICO A (2004) Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide (The prerequisite for its optimal clinical use). *Clin Lab,* 50**,** 325-331.

PAOLETTI E, SPECCHIA C, DI MAIO G, BELLINO D, DAMASIO B, CASSOTTANA P & CANNELLA G (2004) The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. *Nephrol Dial Transplant,* 19**,** 1829.

PARFREY PS, FOLEY RN, HARNETT JD, KENT GM, MURRAY DC & BARRE PE (1996) Outcome and risk factors for left ventricular disorders in chronic uraemia. *Nephrol Dial Transplant,* 11**,** 1277-1285.

PARFREY PS, FOLEY RN, HARNETT JD, KENT GM, MURRAY DC & BARRE PE (1996) Outcome and risk factors for left ventricular disorders in chronic uraemia. *Nephrol Dial Transplant,* 11**,** 1277-1285.

PATTERSON ML, ATKINSON SJ, KNÄUPER V & MURPHY G (2001) Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. *FEBS Lett,* 503**,** 158-162.

PEREIRA AA & SARNAK MJ (2003) Anaemia as a risk factor for cardiovascular disease. *Kidney Int.,* 87**,** (Suppl): S32-S39.

PICKERING TG (1994) Blood pressure measurement and detection of hypertension. *Lancet,* 344**,** 31-35.

PORTOLES J, TORRALBO A, MARTIN P, RODRIGO J, HERRERO J & BARRIENTOS A (1997) Cardiovascular effects of recombinant human erythropoietin in predialysis patients. *Am J Kidney Dis,* 29**,** 541-548.

QUEREJETA R, VARO N, LÓPEZ B, LARMAN M, ARTIÑANO E, ETAYO JC, MARTINEZ UBAGO JL, GUTIERREZ-STAMPA M, EMPARANZA JI, GIL MJ, MONREAL I, MINDAN JP & DIEZ J (2000) Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. *Circulation,* 101**,** 1729-1735.

RAINE AE (1994) Acquired aortic stenosis in dialysis patients. *Nephron,* 68**,** 159.

RANDON RB, ROHDE LE, COMERLATO L, RIBEIRO JP & MANFRO RC (2005) The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis. *Braz J Med Biol Res.,* 38**,** 1409-16.

RASCHER W, TULASSAY T & LANG RE (1985) Atrial natriuretic peptide in plasma of volume-overloaded children with chronic renal failure. *Lancet,* 2**,** 303-305.

RITZ E, LAVILLE M, BILOUS RW, O'DONOGHUE D, SCHERHAG A, BURGER U & DE ALVARO F (2007) Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. *Am J Kidney Dis.,* 49**,** 194-207.

ROMAN MJ, GANAU A, SABA PS, PINI R, PICKERING TG & DEVEREUX RB (2000) Impact of arterial stiffening on left ventricular structure. *Hypertension,* 36**,** 489-494.

ROMAN MJ, PICKERING TG, SCHWARTZ JE, CAVALLINI MC, PINI R & DEVEREUX RB (1997) Is the absence of a normal nocturnal fall in blood pressure (nondipping) associated with cardiovascular target organ damage. *J Hypertens,* 15**,** 969 -978.

ROMAN MJ, PICKERING TG, SCHWARTZ JE, PINI R & DEVEREUX RB (1996) Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults. *J Am Coll Cardiol,* 28**,** 751-756.

ROMAN MJ, SABA PS, PINI R, SPITZER M, PICKERING TG, ROSEN S, ALDERMAN MH & DEVEREUX RB (1992) Cardiac and vascular adaptation in hypertension. *Circulation,* 86**,** 1909-1918.

ROSTAND SG, SANDERS C, KIRK KA, RUTSKY EA & FRASER RG (1988) Myocardial calcification and cardiac dysfunction in chronic renal failure. *Am J Med,* 85**,** 651 -657.

SAFAR ME, BLACHER J, PANNIER B, GUERIN AP, MARCHAIS SJ, GUYONVARC'H PM & LONDON GM (2002) Central pulse pressure and mortality in end-stage renal disease. *Hypertension,* 39**,** 735-8.

SAHN DJ, DEMARIA A, KISSLO J & WEYMAN A (1978) Recommendations regarding Quantitation in M-mode Echocardiography. Results of a survey of Echocardiographic measurements. *Circulation,* 56**,** 1072-1083.

SARNAK MJ & LEVEY AS (2000) Cardiovascular disease and chronic renal disease: A new paradigm. *Am J Kidney Dis,* 35**,** S117- S131.

SAVAGE DD, GARRISON RJ, KANNEL WB, LEVY D, ANDERSON SJ, STOKES J 3RD, FEINLEIB M & CASTELLI WP (1987) The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study. *Circulation,* 75**,** I26-33.

SCHIRMER H, LUNDE P & RASMUSSEN K (2000) Mitral flow derived Doppler indices of left ventricular

diastolic function in a general population.The Tromsø study. *European Heart Journal,* **21,** 1376-1386.

SCHLEIFFER T, NAGEL D, FRANZ H, FALK M, VALENTINER I, WILDBURG G, STARK M & BRASS H (1994) Endothelin and atrial natriuretic peptide in non-insulin dependent diabetic versus nondiabetic patients on chronic hemodialysis. *Renal Failure,* 16**,** 747-758.

SEYREK N, BALAL M, KARAYAYLALI I, PAYDAS S, AIKIMBAEV K, CETINER S & SEYDAOGLU G (2003) Which parameter is more influential on the development of arteriosclerosis in hemodialysis patients? *Ren Fail.,* 25**,** 1011-1018.

SHIBURI CP, STAESSEN JA, MASEKO M, WOJCIECHOWSKA W, THIJS L, VAN BORTEL LM, WOODIWISS AJ & NORTON GR (2006) Reference Values for

SphygmoCor Measurements in South Africans of African Ancestry. *Am J Hypertens,* 19**,** 40-46.

SHINOHARA K, SHOJI T, TSUJIMOTO Y, KIMOTO E, TAHARA H, KOYAMA H, EMOTO M, ISHIMURA E, MIKI T, TABATA T & NISHIZAWA Y (2004) Arterial stiffness in predialysis patients with uremia. *Kidney Int,* 65**,** 936-943.

SHIOTA J, KUBOTA M, HAMADA C & KOIDE H (1990) Plasma atrial. natriuretic peptide during hemodialysis with or without fluid. removal. *Nephron,* 55**,** 283-286.

SHOJI T, EMOTO M, SHINOHARA K, KAKIYA R, TSUJIMOTO Y, KISHIMOTO H, ISHIMURA E, TABATA T & NISHIZAWA Y (2001) Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. *J Am Soc Nephrol,* 12**,** 2117-2124.

SHOKAWA T, IMAZU M, YAMAMOTO H, TOYOFUKU M, TASAKI N, OKIMOTO T, YAMANE K & KOHNO N (2005) Pulse wave velocity predicts cardiovascular mortality:findings from the Hawaii-Los Angeles-Hiroshma study. *Circ J,* 69**,** 259-264.

SILBERBERG JS, BARRE PE, PRICHARD SS & SNIDERMAN AD (1989) Impact of left ventricular hypertrophy on survival in end-stage renal disease. *Kidney Int,* 36**,** 286-290.

SIMM A, NESTLER M & HOPPE V (1998) Mitogenic effect of PDGF-AA on cardiac fibroblasts. *Basic Res Cardiol,* 93**,** 40-3.

SIWIK DA, CHANG DL & COLUCCI WS (2000) Interleukin-1beta and tumor necrosis factor- alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. *Circ Res,* 86**,** 1259-65.

SMILDE TJ, VAN DEN BERKMORTEL FW, WOLLERSHEIM H, VAN LANGEN H, KASTELEIN JJ & STALENHOEF AF (2000) The effect of cholesterol lowering on

carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. *Eur J Clin Invest,* 30**,** 473-480.

SPINALE F G (2002) Matrix metalloproteinases: regulation and dysregulation in the failing heart. *Circ Res,* 90**,** 520-530.

STACK AG & SARAN R (2002) Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. *American journal of kidney diseases,* 40**,** 1202 -10.

STEWART GA, GANSEVOORT RT, MARK PB, STEWART GA, ROONEY E, MCDONAGH TA, DARGIE HJ, STUART R, RODGER C & JARDINE AG (2005) Electrocardiographic abnormalities and uremic cardiomyopathy. *Kidney Int,* 67**,** 217.

STRÓZECKI P, ADAMOWICZ A, NARTOWICZ E, ODROWAZ-SYPNIEWSKA G, WLODARCZYK Z & MANITIUS J (2001) Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. *Ren Fail.,* 23**,** 115-26.

SUNDSTRÖM J, E. J., BENJAMIN EJ, LEVY D, LARSON MG, SAWYER DB, ET AL. (2004) Factors and Echocardiographic Left Ventricular Measures: The Framingham Relations of Plasma Matrix Metalloproteinase-9 to Clinical Cardiovascular Risk. *Circulation,* 109**,** 2850-2856.

SUZUKI K, KATO K, HANYU O, NAKAGAWA O & AIZAWA Y (2001) Left ventricular mass index increases in proportion to the progression of diabetic nephropathy in type 2 diabetic patients. *Diabetes Res Clin Pract.,* 54**,** 173-180.

TAMAKI S (1981) Relationship between ventilatory change in the inferior vena cava and central venous pressure. *Jpn J Soc Thorac Dis.,* 19**,** 460-469.

TORNIG J, AMANN K, RITZ E, NICHOLS C, ZEIER M & MALL G (1996) Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine and moxonidine. *J Am Soc Nephrol,* 7**,** 667-675.

TOZAWA M, ISEKI K, ISEKI C & TAKISHITA S (2002) Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. *Kidney Int,* 61**,** 717-726.

TYCHO VUURMANS JL, BOER WH, BOS WJ, BLANKESTIJN PJ & KOOMANS HA (2002) Contribution of volume overload and angiotensin II to the increased pulse wave velocity of hemodialysis patients. *J Am Soc Nephrol,* 13**,** 177-183.

TYRALLA K & AMANN K (2003) Morphology of the heart and arteries in renal failure. *Kidney Int,* 63**,** S80-S83.

U.S. RENAL DATA SYSTEM (2006) USRDS 2005 annual data report. *Am J Kidney Dis,* 47**,** S1.

ULASI II, ARODIWE EB & IJOMA CK (2006) Left ventricular hypertrophy in African Black patients with chronic renal failure at first evaluation. *Ethn Dis,* 16**,** 859-64.

UNITED STATES RENAL DATA SYSTEM: (1999.) USRDS 1999 Annual Data Report. Bethesda, National Institutes of Health,NIDDK.

VALDERRABANO F, JONES EHP & MALLICK NP (1995) Report on management of renal failure in Europe, XXIV, 1993. *Nephrol Dial Transpl,* 10**,** 1-25.

VANDERHEYDEN M, BARTUNEK J & GOETHALS M (2004) Brain and other natriuretic peptides: molecular aspects. *Journal of Heart Failure,* 6**,** 261-268.

VICKERY S, PRICE CP, JOHN RI, ABBAS NA, WEBB MC, KEMPSON ME & LAMB EJ (2005) B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in Patients

With CKD: Relationship to Renal Function and Left Ventricular Hypertrophy. *Am J Kidney Dis,* 46**,** 610-620.

WAHL H, GRAF S, RENZ H & FASSBINDER W (2004) Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. *Clin Chem.,* 50**,** 1071-1074.

WANIC-KOSSOWSKA M, LEHMANN P & CZEKALSKI S (2002) Left ventricular hypertrophy in patients with chronic renal failure treated by hemodialysis. *Arch Med Wewn,* 107**,** 539-46.

WATKINS LO (1984) Coronary heart disease and coronary disease risk factors in black populations in underdeveloped countries. The case for primodial prevention. *Am Heart J,* 108**,** 850-862.

WEBER KT, SUN Y, TYAGI SC & CLEUTJENS JP (1994) Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. *J Mol Cell Cardiol,* 26**,** 279-92.

WEIL F & MAURAT P (1974) The sign of the vena cava: echotomographic illustration of right cardiac insufficiency. *J Clim Ultrasound,* 2**,** 27-32.

WEINER DE, NICHOLLS AJ & SARNAK MJ (2007) *Handbook of Dialysis.*, Philadelphia, Lippincott Williams and Wilkins.

WILKINSON IB, FRANKLIN SS, HALL IR, TYRRELL S & COCKCROFT JR (2001) Pressure amplification explains why pulse pressure is unrelated to risk in young subjects. *Hypertention,* 38**,** 1461-1466.

WILKINSON IB, MOHAMMAD NH, TYRELL S, HALL IR, WEBB DJ, PAUL VE, LEVY T & COCKCROFT JR (2002) Heart rate dependency of pulse pressure amplification and arterial stiffness. *AJH,* 15**,** 24-30.

YASMIN & BROWN MJ (1999) similarities and differences between augmentation index and pulse wave velocity in the assessment of arterial stiffness. *Q J Med,* 92**,** 595-600.

YASMIN, WALLACE S, MCENIERY C M, DAKHAM Z, PUSALKAR P, MAKI-PETAJA K, ASHBY MJ & COCKCROFT JR (2005) Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity Are Associated With Systolic Hypertension and Arterial Stiffness. *Arteriosclerosis, Thrombosis, and Vascular Biology,* 25**,** 372.

ZABALGOITIA M, BERNING J, KOREN MJ, STØYLEN A, NIEMINEN MS, DAHLO¨F B, DEVEREUX RB & FOR THE LIFE STUDY INVESTIGATORS (2001) Impact of Coronary Artery Disease on Left Ventricular Systolic Function and Geometry in Hypertensive Patients With Left Ventricular Hypertrophy (The LIFE Study). *Am J Cardiol,* 88**,** 646-650.

ZAGER PG, NIKOLIE J, BROWN RH, CAMPBELL MA, HUNT WC, PETERSON D, VAN STONE J, LEVEY A, MEYER KB, KLAG MJ, JOHNSON HK, CLARK E, SADLER JH & TEREDESAI P (1998) "U" curve association of blood pressure and mortality in haemodialysis patients. *Kidney Int,* 54**,** 561-569.

ZOCCALI C, CICCARELLI M, MALLAMACI F, DELFINO D, SALNITRO F, PARLONGO S & MAGGIORE Q (1986) Effect of ultrafiltration on plasma concentrations of atrial natriuretic peptide in haemodialysis patients. *Nephrol Dial Transplant,* 1**,** 188-191.

ZOCCALI C, MALLAMACI F, TRIPEPI G, BENEDETTO FA, COTTINI E, GIACONE G & MALATINO L (1999) Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients. *Journal of Hypertension,* 12**,** 1751-1758.

ZOUNGAS S, KERR PG, CHADBAN S, MUSKE C, RISTEVSKI S, ATKINS RC, MCNEIL JJ & MCGRATH BP (2004) Arterial function after successful renal transplantation. *Kidney Int.,* 65**,** 1882-1889.